GSK will incorporate the findings into messaging that depemokimab patients will adhere to treatment better, ensuring better ...

Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary for response.

Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma [ID6334] Technology appraisal guidance 7 May 2025 Brexucabtagene autoleucel for treating relapsed or ...

MANILA, Philippines — GSK plc (LSE/NYSE: GSK) has today released global survey data showing that over half (52%) of people aged 50-60 feel younger than their age—and nearly a fifth (19% ...

GSK will also present an analysis of the relationship between risk of severe exacerbation and healthcare burden in patients with COPD. Updates from SWIFT-1 and SWIFT-2, the trials assessing the ...

Two of the treatments that will be receiving plenty of attention in GSK’s presentations are mepolizumab and depemokimab, which are both monoclonal antibodies (mAbs) that target IL-5, a key cytokine or ...

GlobalData is the parent company of Clinical Trials Arena. Elsewhere in asthma, GSK is hoping for approval of its depemokimab as an add-on treatment for asthma after two Phase III trials, SWIFT-1 and ...

GSK plc (NYSE:GSK) Q1 2025 Earnings Call Transcript ... we continue to expect FDA approvals for Nucala COPD imminently, Blenrep in July, and depemokimab by the end of the year.

GSK said it remains confident it can absorb the financial impact of potential US tariffs as it posted a 4% rise in Q1 2025 sales.

GSK reported 4% year-on-year earnings growth ... Blenrep's application in second-line multiple myeloma (July 23), and depemokimab's application in severe asthma (end of the year).